2Dailey G,Rosenstock J,Moses RG,et al.Insulin glulisin provides improved glycemic control in patients with type 2diabetes[J].Diabetes Care,2004,27 (10):2 363.
3Timmins P,Donahue S,Meeker J,et al.Steady-state pharmacokinetics of a novel extended-release metformin formulation[J].Clin Pharmacokinet,2005,44 (7):721..
4Defang O,Shufang N,Wei L,et al.In vitro and in vivo evaluation of two extended release preparations of combination mefformin and glipizide[J].Drug Dev Ind Pharm,2005,31(7):677.
5Hughes RC,Gardiner SJ,Begg EJ,et al.Effect of pregnancy on the pharmacokinetics of metformin[J].Diabet Med,2006,23(3):323.
9Schwartz SL,Wu JF,Berner B.Metformin extended release for the treatment of type 2 diabetes mellitus[J].Expert Opin Pharmacother,2006,7 (6):803.
10Schwartz S,Fonseca V,Berner B,et al.Efficacy,tolerability,and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes[J].Diabetes Care,2006,29(4):759.
2Vesterqvist O, Nabbie F, Swanson B. Determination of plasma by high-performance liquid chromatography after ultrafiltration[ J ]. J Chromatogr B Biormed Sci Appl, 1998,716( 1 ～2) :299 - 304.
3Gilles C, Yves L, Manon R, et al. Bioavailability of metformin in tablet form using a new high pressure liquid chromatography assay method[ J ]. Biopharmaceu Drug Dispo, 1993,114: 257 - 263.
4Huupponen R, Ojaia-Karlsson P, Rouru J, et al. Determination ofmetformin in plasma by high-performance liquid chromatography[J]. J Chromatogr, 1992,583: 270 - 273.
